Fabio Catalano

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications

Corrigendum to "Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer": [ESMO Gastrointestinal Oncology, Volume 5, 100069].

Corrigendum to "Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer": [ESMO Gastrointestinal Oncology, Volume 5, 100069].

Journal: ESMO gastrointestinal oncology
Published: April 17, 2026

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Journal: The oncologist
Published: December 16, 2025

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

Journal: The oncologist
Published: December 16, 2025

Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.

Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.

Journal: Frontiers in oncology
Published: November 25, 2025

Evidence of Nuclear Geometry-Driven Anisotropic Flow in O+O and Ne+Ne Collisions at sqrt[s_{NN}]=5.36  TeV.

Evidence of Nuclear Geometry-Driven Anisotropic Flow in O+O and Ne+Ne Collisions at sqrt[s_{NN}]=5.36  TeV.

Journal: Physical review letters
Published: September 18, 2025

Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

Journal: Physical review letters
Published: April 28, 2025

Evidence for J/ψ Suppression in Incoherent Photonuclear Production.

Evidence for J/ψ Suppression in Incoherent Photonuclear Production.

Journal: Physical review letters
Published: April 12, 2025

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Journal: Physical review letters
Published: October 30, 2024

First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.

Journal: Physical review letters
Published: October 29, 2024

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

Journal: Immunotherapy
Published: August 19, 2024

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.

Journal: Immunotherapy
Published: August 06, 2024

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.

Journal: Clinical genitourinary cancer
Published: July 30, 2024
Showing 1-12 of 78

Last Updated: 09/26/2026